Abstract: The present application relates to novel combinations of at least two components, component A and component B: component A is an IRAK4-inhibiting compound of the formula (I) as defined herein, or a diastereomer, an enantiomer, a metabolite, a salt, a solvate or a solvate of a salt thereof; component B is a BTK-inhibiting compound, or a pharmaceutically acceptable salt thereof; and, optionally, one or more components C which are pharmaceutical products; in which one or two of the above-defined compounds A and B are optionally present in pharmaceutical formulations ready for simultaneous, separate or sequential administration, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis.

Abstract: The present invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.

Abstract: The present disclosure relates to substituted thiophene carboxamides and analogues thereof of formula (I) that may be used for protecting plants from bacterial diseases, in particular from bacterial diseases caused by bacteria belonging to the genus Xanthomonas.

Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to the application of plant protection agents, fertilisers and/or pesticides by means of a (preferably portable) sprayer or a small appliance (such as, for example, a bicycle tyre sealant injector). The present invention relates to a monitoring module with which existing sprayers can be equipped in order to control, track and/or document the spraying process. The present invention further relates to a method, a system and a computer program product for monitoring spraying processes.

Abstract: The present invention relates to a novel and improved process for preparing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid of the formula (I), to the compound of the formula (I) in crystalline form and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular, cardiopulmonary and cardiorenal disorders.

Abstract: The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula (I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to compounds of formula (1) in which A, U and R1 are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant KRAS signaling, as a sole agent or in combination with other active ingredients.

Abstract: A pressure jacket configured for connecting to an injector head of a fluid injector has an open distal end, an open proximal end, and a sidewall defining a throughbore extending between the distal end and the proximal end along a longitudinal axis. The throughbore is configured for receiving at least a portion of a syringe. The pressure jacket has at least one syringe retaining element positioned at least partially within the throughbore. The at least one syringe retaining element is configured for engaging at least a portion of the syringe during pressurized delivery of fluid from the syringe to prevent or limit a distal movement of the syringe relative to the pressure jacket.

Abstract: The invention relates to substituted phenylpyrimidines of general formula (I), to their agrochemically acceptable salts (I), and to the use thereof in the field of plant protection.

Abstract: A method is described for production of a high purity compound of the formula (I) in crystalline form of the modification A. In this, starting from high purity gadobutrol, the gadolinium is removed by decomplexation with oxalic acid, and then with a calcium salt the calcium complex is produced in high purity. During the crystallization, a water equivalent of 9-11 weight % is set. The crystalline form of the modification A of the compound of the formula (I) is used in the production of Gadovist.

Abstract: The disclosure provides for methods for preparing 2-cyanoimino-1,3-thiazolidine, which is an important building block for the preparation of crop protection active ingredients and pharmaceuticals. To this end, the disclosure provides for more efficient and improved methods of preparing 2-cyanoimino-1,3-thiazolidine.

Abstract: The present invention relates to ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular arylquinolizine derivatives of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: The present invention relates to the identification of one or more candidate signs indicative of an NTRK oncogenic fusion within patient data. Subject matter of the present invention are a computer-implemented method, a system, and a non-transitory computer-readable storage medium for determining a probability value from patient data associated with a subject patient, the probability value indicating the probability of the subject patient suffering from cancer caused by a mutation of a neurotrophic receptor tyrosine kinase (NTRK) gene.

Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular diazabicyclically substituted imidazo [1,2-a]pyrimidine derivatives and ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular arylquinolizine derivatives of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: The present invention relates to agrochemical compositions: their use for foliar application; their use at low spray volumes; their use by unmanned aerial systems (UAS), unmanned guided vehicles (UGV), and tractor mounted boom sprayers fitted with conventional nozzles but also pulse width modulation spray nozzles or rotating disc droplet applicators; and their application for controlling agricultural pests, 10 weeds or diseases, in particular on waxy leaves.

Abstract: The present invention relates to agrochemical compositions: their use for foliar application; their use at low spray volumes; their use by unmanned aerial systems (UAS), unmanned guided vehicles (UGV), and tractor mounted boom sprayers fitted with conventional nozzles but also pulse width modulation spray nozzles or rotating disc droplet applicators; and their application for controlling agricultural pests, weeds or diseases, in particular on waxy leaves.

Abstract: The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives and ?2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular aryl piperazines of formula (I) for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring.

Abstract: An injector system for injecting fluid includes a syringe and an injector. The syringe includes a body and a plunger movably disposed within the body. The plunger has at least one flexible leg extending toward the rearward end of the body. The injector has a housing with a front plate, a drive member at least partially disposed within the housing and operable to engage the plunger, and a syringe release assembly operable to release the syringe. The syringe assembly includes a syringe release gear that forms an enclosure for receiving the syringe when the syringe is fully seated within the housing and a plunger release tube surrounding at least a portion of the drive member. The plunger release tube has a first end rotationally engaged with the syringe release gear. Rotation of the syringe release assembly releases the at least one flexible leg from the drive member.

Abstract: The present invention refers to a pharmaceutical preparation (10) comprising a first pharmaceutical composition having a matrix material and pharmaceutically active ingredients distributed within the matrix material, wherein the first pharmaceutical composition comprises Praziquantel, Pyrantel and Febantel as pharmaceutical active ingredients, wherein the preparation (10) comprises a second pharmaceutical composition having a matrix material and at least one of avermectins and milbemycins such as Moxidectin as pharmaceutically active ingredient distributed within the matrix material, wherein the preparation (10) is provided in a multi-layer structure such, that the first composition is provided in a first layer (12) and the second composition is provided in a second layer (14), wherein the first layer (12) and the second layer (14) are separated by a barrier layer (16) being provided between the first layer (12) and the second layer (14).